Massage therapy for osteoarthritis of the knee: a randomized dose-finding trial
- PMID: 22347369
- PMCID: PMC3275589
- DOI: 10.1371/journal.pone.0030248
Massage therapy for osteoarthritis of the knee: a randomized dose-finding trial
Abstract
Background: In a previous trial of massage for osteoarthritis (OA) of the knee, we demonstrated feasibility, safety and possible efficacy, with benefits that persisted at least 8 weeks beyond treatment termination.
Methods: We performed a RCT to identify the optimal dose of massage within an 8-week treatment regimen and to further examine durability of response. Participants were 125 adults with OA of the knee, randomized to one of four 8-week regimens of a standardized Swedish massage regimen (30 or 60 min weekly or biweekly) or to a Usual Care control. Outcomes included the Western Ontario and McMaster Universities Arthritis Index (WOMAC), visual analog pain scale, range of motion, and time to walk 50 feet, assessed at baseline, 8-, 16-, and 24-weeks.
Results: WOMAC Global scores improved significantly (24.0 points, 95% CI ranged from 15.3-32.7) in the 60-minute massage groups compared to Usual Care (6.3 points, 95% CI 0.1-12.8) at the primary endpoint of 8-weeks. WOMAC subscales of pain and functionality, as well as the visual analog pain scale also demonstrated significant improvements in the 60-minute doses compared to usual care. No significant differences were seen in range of motion at 8-weeks, and no significant effects were seen in any outcome measure at 24-weeks compared to usual care. A dose-response curve based on WOMAC Global scores shows increasing effect with greater total time of massage, but with a plateau at the 60-minute/week dose.
Conclusion: Given the superior convenience of a once-weekly protocol, cost savings, and consistency with a typical real-world massage protocol, the 60-minute once weekly dose was determined to be optimal, establishing a standard for future trials.
Trial registration: ClinicalTrials.gov NCT00970008.
Conflict of interest statement
Figures



References
-
- Arden N, Nevitt M. Osteoarthritis:epidemiology. Best Pract Res Clin Rheumatol. 2006;20:3–25. - PubMed
-
- Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, et al. Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials 1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clin Ther. 2005;27:1196–1214. - PubMed
-
- Kato T, Xiang Y, Nakamura H, Nishioka K. Neoantigens in osteoarthritic cartilage. Curr Opinion Rheumatol. 2004;16:604–608. - PubMed
-
- Fisher N, Pendergast D. Reduced muscle function in patients with osteoarthritis. Scand J Rehab Med. 1997;29:213–221. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical